NCT04945772: An ongoing trial by Nanoscope Therapeutics Inc.
This trial is ongoing. It must report results 1 month, 2 weeks ago.
Full data
Full entry on ClinicalTrials.gov | NCT04945772 |
---|---|
Title | A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | July 13, 2021 |
Completion date | Feb. 27, 2023 |
Required reporting date | Feb. 27, 2024, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |